Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Fiorella Ruiz-Pace"'
Autor:
Elena Élez, Núria Mulet-Margalef, Miriam Sanso, Fiorella Ruiz-Pace, Francesco M. Mancuso, Raquel Comas, Javier Ros, Guillem Argilés, Giulia Martini, Enrique Sanz-Garcia, Iosune Baraibar, Francesc Salvà, Alba Noguerido, Jose Luis Cuadra-Urteaga, Roberta Fasani, Ariadna Garcia, Jose Jimenez, Susana Aguilar, Stefania Landolfi, Javier Hernández-Losa, Irene Braña, Paolo Nuciforo, Rodrigo Dienstmann, Josep Tabernero, Ramon Salazar, Ana Vivancos
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 1, p 118 (2022)
The search for immunotherapy biomarkers in Microsatellite Instability High/Deficient Mismatch Repair system (MSI-H/dMMR) metastatic colorectal cancer (mCRC) is an unmet need. Sixteen patients with mCRC and MSI-H/dMMR (determined by either immunohisto
Externí odkaz:
https://doaj.org/article/f77ab85a817d47428099bae4d6a1c90a
Autor:
Rodrigo Dienstmann, Elena Elez, Guillem Argiles, Ignacio Matos, Enrique Sanz‐Garcia, Carolina Ortiz, Teresa Macarulla, Jaume Capdevila, Maria Alsina, Tamara Sauri, Helena Verdaguer, Marta Vilaro, Fiorella Ruiz‐Pace, Cristina Viaplana, Ariadna Garcia, Stefania Landolfi, Hector G. Palmer, Paolo Nuciforo, Jordi Rodon, Ana Vivancos, Josep Tabernero
Publikováno v:
Molecular Oncology, Vol 11, Iss 9, Pp 1263-1272 (2017)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (MAFs, or the ‘mutation dose’) of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. We perfor
Externí odkaz:
https://doaj.org/article/db9cadd2428d4ebebd17baf85c373983
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
Autor:
Victor Rodriguez-Freixinos, Fiorella Ruiz-Pace, Lorena Fariñas-Madrid, Ana Christina Garrido-Castro, Guillermo Villacampa, Paolo Nuciforo, Ana Vivancos, Rodrigo Dienstmann, Ana Oaknin
Publikováno v:
ESMO Open, Vol 4, Iss 2 (2019)
Objectives Aberrant PI3K/AKT/mTOR activation is common in gynaecological malignancies. However, predictive biomarkers of response to PI3K pathway inhibitors (PAMi) have yet to be identified.Methods We analysed the outcomes of patients with advanced g
Externí odkaz:
https://doaj.org/article/cd76a2bf7a594e9cbafdf669d57b56f7
Autor:
Garazi Serna, Eloy García, Roberta Fasani, Xavier Guardia, Tomas Pascual, Laia Paré, Fiorella Ruiz-Pace, Antonio Llombart-Cussac, Javier Cortes, Aleix Prat, Paolo Nuciforo
Breast cancer is a heterogeneous disease. Tumor cells and the surrounding microenvironment form an ecosystem that determine disease progression and response to therapy. To characterize the breast cancer ecosystem and the changes induced by targeted t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eefdc866385e06c46260f796ea38a7b6
https://doi.org/10.1101/2022.09.21.508826
https://doi.org/10.1101/2022.09.21.508826
Autor:
Mireia Parés, Javier Cortes, Marta Guzman, Cristina Viaplana, Rodrigo Dienstmann, Alejandra Bruna, Carlos Caldas, Fiorella Ruiz-Pace, Albert Gris-Oliver, Patricia Cozar, Pilar Anton, Antonio Llombart-Cussac, Violeta Serra, Mònica Sánchez-Guixé, Martín A. Rivas, Jose Perez-Garcia, Celina Garcia-Garcia, Paolo Nuciforo, Joaquín Arribas, Olga Rodriguez, Maria Teresa Calvo, Judit Grueso, Mafalda Oliveira, Yasir H. Ibrahim
Publikováno v:
Br J Cancer
BACKGROUND: Eribulin is a microtubule-targeting agent approved for the treatment of advanced or metastatic breast cancer (BC) previously treated with anthracycline- and taxane-based regimens. PIK3CA mutation is associated with worse response to chemo
Autor:
Francesc Salva, Rafael Paes, Matheus Costa e Silva, Heloisa Cruz, Nadia Saoudi Gonzalez, Iosune Baraibar, Javier Ros Montañá, Raquel Comas, Fiorella Ruiz-Pace, Ariadna Garcia, Renata Dalpino, Alexandre A. Jácome, Josep Tabernero, Elena Elez, Rodrigo Dienstmann
Publikováno v:
Journal of Clinical Oncology. 41:153-153
153 Background: Oxaliplatin is a backbone cytotoxic treatment for mCRC patients, particularly in the front-line setting. In the refractory disease, current treatment options are scarce and with limited efficacy. Several retrospective studies have exp
Autor:
Roberta Fasani, Stefania Landolfi, Sheeno Thyparambil, Fiorella Ruiz-Pace, Fabiola Cecchi, Paolo Nuciforo, Garazi Serna, Elena Elez, José Antonio Jiménez, Rodrigo Dienstmann, Josep Tabernero, Todd Hembrough, Ana Vivancos
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Scientific Reports
Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Scientific Reports
Biomarcadores del cáncer; Cáncer metástico colorrectal; Terapias experimentales Cancer biomarkers; Colorectal metastatic cancer; Experimental therapies Biomarcadors del càncer; Càncer metastàtic colorrectal; Teràpies experimentals Protein biom
Autor:
Alberto Gonzalez-Medina, Andri Papakonstantinou, Judit Matito, Fiorella Ruiz-Pace, Meritxell Bellet, Anna Suñol, Miriam Arumí, Esther Zamora, Carolina Ortiz, Lucia Sanz, Patricia Gómez Pardo, Marina Gómez-Rey, Roberta Fasani, Clara Morales, Vicente Peg, Paolo Nuciforo, Rodrigo Dienstmann, Cristina Saura, Ana Vivancos, Mafalda Oliveira
Publikováno v:
Journal of Clinical Oncology. 40:1061-1061
1061 Background: Molecular characterization of LMBC for the choice of therapy and inclusion in clinical trials is frequently performed in archival biopsies procured several years before. Emerging mut secondary to therapeutic pressure are hence freque
Autor:
Andri Papakonstantinou, Alberto Gonzalez-Medina, Judit Matito, Marta Ligero, Fiorella Ruiz-Pace, Anna Suñol, Joaquin Rivero, Roberta Fasani, Mara Cruellas, Vicente Peg, Maria Borrell, Isabel Pimentel, Santiago Escriva De Romani Munoz, Judith Balmana Gelpi, Paolo Nuciforo, Rodrigo Dienstmann, Cristina Saura, Raquel Perez-Lopez, Mafalda Oliveira, Ana Vivancos
Publikováno v:
Journal of Clinical Oncology. 40:1086-1086
1086 Background: Genomic alterations driving MBC progression may be better captured by ctDNA reflecting clonal evolution, but it is currently unknow whether ctDNA analysis can replace tumor sequencing for clinical decision purposes. Aim: to study the
Autor:
Elisa Llurba, Cristina Saura, Maria Concepció Céspedes, O. Sánchez, Rodrigo Dienstmann, Ángeles Peñuelas, Javier Cortes, Sandra Patricia Martínez, Carmen Domínguez, Fiorella Ruiz-Pace, Octavi Cordoba
Publikováno v:
Cancers
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Scientia
Cancers, Vol 13, Iss 923, p 923 (2021)
Volume 13
Issue 4
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Scientia
Cancers, Vol 13, Iss 923, p 923 (2021)
Volume 13
Issue 4
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
High prevalence of placental-derived complications, such as preeclampsia and intrauterine growth restriction, has been reported in women with breast cancer (BC) treated with chemotherapy during pregnancy (PBC-CHT). Aim: To ascertain whether PBC-CHT i